Agilent Technologies to Acquire Advanced Analytical Technologies, Inc.
“This acquisition is another great example of Agilent effectively deploying our capital to create value for our customers and our shareholders. AATI’s complementary products strengthen our existing strong portfolio of solutions and provide further opportunities to accelerate our growth,” said Patrick Kaltenbach, president of Agilent’s Life Sciences and Applied Markets Group.
Automated electrophoresis is a commonly used separation technique to analyze biomolecules such as nucleic acids (RNA and DNA), proteins, carbohydrates and small molecules. It has a broad range of applications and is used across a variety of industries segments including pharma and biopharma, academia and government, clinical and diagnostics, food, environmental and forensics, and chemical and energy.
AATI has developed compelling CE technologies that provide key advances in sensitivity and resolution to address a wide range of applications. AATI solutions are comprised of instruments, software and consumables aimed at simplifying complex workflows.
“Technology advances in genomics, metabolomics, and proteomics are driving growth and demand for innovative new solutions,” said Dr. Stefan Schuette, vice president and general manager of Agilent’s Liquid Phase Separations Division. “The value of this acquisition is in the expanded capabilities for emerging applications that Agilent and AATI together can offer.”
“Each company brings expertise and a culture of innovation,” said Steven J. Lasky, Ph.D., AATI CEO. “I believe we will be able to serve customers better and provide even greater opportunities for our employees by joining Agilent.”
Founded in 1998, AATI is based in Ankeny, Iowa and employs 101 employees.
The transaction is subject to customary closing conditions and regulatory approval.